



Supplementary Information


Structural insights into trans-histone regulation of H3K4
methylation by unique histone H4 binding of MLL3/4

Liu, et al.




Supplementary Fig. 1 ITC titration curves for different histone peptides to the extended PHD₆ domains (ePHD₆) of MLL3 and MLL4. NB: no detectable binding. Related to Table 1.








Supplementary Fig. 3 Superimposition of gel-filtration curves of PHD₆ and ePHD₆ domains of MLL3 and MLL4. Gel filtration chromatography of MLL3 ePHD₆ (red), PHD₆ (pink), MLL4 ePHD₆ (brown), PHD₆ (green) and protein molecular weight standards (blue, Bio-Rad). Samples were loaded to the Superdex200 10/300 GL (GE Healthcare) column in the buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 50 µM ZnCl₂, and 1 mM DTT.




Supplementary Fig. 4 ITC titration curves for different histone H4 mutant peptides to the extended PHD₆ domains (ePHD₆) of MLL3 and MLL4. NB: no detectable binding. Related to Fig. 2h.

a


	1 0 8 0	1 0 9 0	1 1 0 0	1 1 1 0	1 1 2 0	1 1 3 0	1 1 4 0
MLL3_PHD6	.	CPV	C	Q	A	V	.
MLL4_PHD6	1080 PCASLSS	CPV	CYRNYREEDLI	LQ	CRQ	CDRW	MH
DmLPT_PHD6	1500 PCASLVT	CP	I	CHAPYVEEDLL	I	Q	CERWMH
BPTF_PHD2	651 SCTSQSS	CPV	CKVSYNSNGEMI	IQ	CEH	CELWAH	FH
MLL5_PHD	2863 KKDTKLYC.	ICKTP	YDESKF	YIGCD	R	CQN	WYHGR
BHC80_PHD	114 YGTDVTRC.	ICGFTH	.DDGYM	IC	DKCSV	WQHID	CGV
UHRF1_PHD	484 GDI HED	FCS	VCR	...KSGQL	LMCDT	CSRVY	HLD
	324 RLCRVCAC	CHI	CGGRQ	.DPDK	QLM	CDMAFEI	Y

b**c****d**MLL3-H4₁₋₂₀**e**

Model of MLL3-H3K4me3

**f**


BPTF-H3K4me3 (2F6J)



BHC80-H3K4me0 (2PUY)


g

MLL5-H3K4me3 (4L58)




UHRF1-H3R2me0 (3SOW)

Supplementary Fig. 5 Structural comparison to other PHD domains. a Sequence alignment of different PHD domains. Residues involved in ligand binding are highlighted by black stars for MLL3 PHD6 and different colors for the other PHD domains. **b-g** Cartoon representation of different PHD domains. The bound histone peptides are shown in stick models.




Supplementary Fig. 6: Electrostatic surface representation of different PHD domains.
The bound Peptides are shown in stick models.




c

MLL3/MLL4 constructs	<i>K_d</i> (μM)
	H4 ₁₁₋₂₁ K16me3
MLL3_(ePHD ₆)	48 ± 5
MLL3_I1100L	34 ± 2
MLL4_(ePHD ₆)	14 ± 1
MLL4_L1520I	31 ± 1

Supplementary Fig. 7 Trimethylation of H4K16 affects histone H4 binding to MLL3 and MLL4 differently. ITC titration curves (**a** and **b**) and affinity table (**c**) for the titration of H4₁₁₋₂₁K16me3 to the ePHD₆ domain of wt MLL3, MLL3_I1100L mutant, wt MLL4 and MLL4_L1520I mutant.




Supplementary Fig. 8 Western blot analysis of immunoprecipitation eluates of proteins from different flag-tagged MLL3/MLL4 constructs. The antibodies used for this assays are as following:




Supplementary Fig. 9 Nucleosome pull-down assay. Pull-down of wild type and mutant recombinant nucleosomes by GST-tagged ePHD₆ of MLL3/4, which was then detected by western blot analysis with anti-H4 specific antibody (Abcam, ab174628). The anti-H4 antibody is generated using the C-terminus of histone H4 as the antigen

Original scan for Fig. 3b

Long exposure for
[³H]-Methyl




Short exposure for
[³H]-Methyl



anti-FLAG



[³H]-Methyl



anti-FLAG

anti-H3


anti-H3



Original scan for Fig. 3d and 3e


[³H]-Methyl

3d



[³H]-Methyl


3e



anti-H3


3d

3e




Supplementary Fig. 10 Original scan for Fig. 3

Original scan for Fig. 4a




Supplementary Fig. 11 Original scan for Fig. 4a

Original scan for Supplementary Fig. 8



Supplementary Fig. 12 Original scan for Supplementary Fig. 8



Supplementary Fig. 13 Original scan for Supplementary Fig. 9

Supplementary Table 1 Primer sequences

Protein fragments	Sequences
<i>E. coli</i> expression constructs ^a	
MLL3_(ePHD ₆) ₁₀₅₅₋₁₁₄₄	5': gttccgcgtggtagtGTTGGTGCAGACACTGTGG 3': caagcttcgtcatcaATTAGACGCAGGCATATAAGGG
MLL3_(ePHD ₆) ₁₀₇₅₋₁₁₄₄	5': gttccgcgtggtagtTACACACAGTGCCTCCTTG 3': caagcttcgtcatcaATTAGACGCAGGCATATAAGGG
MLL3_(PHD ₆) ₁₀₈₅₋₁₁₄₄	5': gttccgcgtggtagtTCTCCTGTCCAGTCTGCTATC 3': caagcttcgtcatcaATTAGACGCAGGCATATAAGGG
MLL3_(PHD ₅) ₁₀₀₉₋₁₀₅₅	5': gttccgcgtggtagtGTGTGTGAGGCCTGTGGGAAG 3': caagcttcgtcatcaAACACACCATTGCACCTCCAG
MLL3_(PHD ₅₋₆) ₁₀₀₈₋₁₁₄₄	5': gttccgcgtggtagtACTGTGTGAGGCCTGTGG 3': caagcttcgtcatcaATTAGACGCAGGCATATAAGGG
MLL3_(ePHD ₃) ₄₃₆₋₅₂₅	5': gttccgcgtggtagtCGTATTGCATTGAATGCGGTAC 3': caagcttcgtcatcaATCCATTCCGCAGCCCAGATG
MLL4_(ePHD ₆) ₁₄₇₅₋₁₅₆₄	5': gttccgcgtggtagtGTGCCTGTATGCAGTGTGG 3': caagcttcgtcatcaCACAGGCTTACCACGTAGG
MLL4_(ePHD ₆) ₁₄₉₅₋₁₅₆₄	5': gttccgcgtggtagtTACACACACTGTGGGCCCTG 3': caagcttcgtcatcaCACAGGCTTACCACGTAGG
MLL4_(ePHD ₆) ₁₅₀₅₋₁₅₆₄	5': gttccgcgtggtagtGTGACCTGCCCTATCTGTCAATG 3': caagcttcgtcatcaCACAGGCTTACCACGTAGG
MLL4_(PHD ₅) ₁₄₂₉₋₁₄₇₅	5': gttccgcgtggtagtGTGTGTGAGGTGTGTGGCC 3': caagcttcgtcatcaCACACACCATTGCACCTCC
Mutants ^b	
MLL3_ePHD ₆ (E1097A)	5': CGAAACTATAGAGAAgctGATCTTATTCTGCAA 3': TTGCAGAATAAGATCagcTTCTCTATAAGTTCG
MLL3_ePHD ₆ (W1109A)	5': AGACAATGTGATAGAgcgATGCATGCAGTTGT 3': ACAAACTGCATGCATCgcTCTATCACATTGTCT
MLL3_ePHD ₆ (E1120A)	5': CAGAACTTAAATACTgcgGAAGAAGTGGAAAAT 3': ATTTCCACTTCTTCgcAGTATTAAAGTTCTG
MLL4 fusion-2M	
MLL4 fusion(W1529A)	5': CGCCACTGTGAACGGgcgATGCATGCAGGCTG 3': CAGCCTGCATGCATCgcCCGTTCACAGTGGCG
MLL4 fusion(E1540A)	5': GAGCCTCTCACAgcgGACGATGTGGAGC 3': GCTCCACATCGTCgcTGTGAAGAGGGCTC
Nucleosome mutants	
H4-1-5 to G	5': ATGggaGGCggaGGAggaGGCGGAAAAGGC 3': GCCTTTCCGCCtccTCCtccGCCtccCAT
H4-15-19 to G	5': GGGGGCggaggaggaggagaAAGGTCTTG 3': CAAGACCTTccctccctcccccGCC

H4_R3A	5': ATGTCCGGCgcaGGAAAGGGCGGAAAAGGC 3': GCCTTTCCGCCCTTCCtgcGCCGGACAT
H4_R17A	5': AAAGGGGGCGCTAACGgccCACCGCAAGGTC 3': GACCTTGCAGGTGggcCTTAGCGCCCCCTTT
H4_H18A	5': AAAGGGGGCGCTAACGCGCgcaCGCAAGGTC 3': GACCTTGCAGtgcGCGCTTAGCGCCCCCTTT
Mammalian expression constructs^c	
MLL3_C ₃₉₉₃₋₄₉₁₁	5': <u>ccatcgata</u> GGTGATCGAGATACTCCTGAC 3': <u>gggttacctc</u> GTTCATCCACTCCGGCAGTTC
MLL3_(ePHD ₆) ₁₀₅₅₋₁₁₄₄	5': ataaga <u>atgcggcccg</u> TACACACAGTGCCTCCTTG 3': <u>ggaattcgc</u> ATTAGACGCAGGCATATAGGG
MLL3_(ePHD4. ₆) ₉₃₉₋₁₁₄₄	5': ataaga <u>atgcggcccg</u> TCTATGCACAATACAGTTGTGTTG 3': <u>ggaattcgc</u> ATTAGACGCAGGCATATAGGG
Quantitative RT-PCR	
HOXA1	5': TTCTCCGGCCCCATGG 3': GAGTGACCTGGTCCTGCGAA
HOXA2	5': TTTCATACCGTAGGGCTCGG 3': CCCTGCTGGTAACTTCCAACAG
HOXA3	5': TGCTTGTTGTTTGTCGAGACTC 3': CAACCCCTACCCCTGCCAAC
NANOG	5': TTTGTGGGCCTGAAGAAA 3': AGGGCTGTCCCTGAATAAGCAG
NeuN	5': CCAAGCGGCTACACGTCTC 3': CGTCCCATTAGCTTCTCCC

Note: a, the lower cases of these primers are the sequences used by T4 ligase-independent cloning;
 b, the lower cases of these primers are the mutation sites; c, the lower cases of these primers are the sequences associated with restriction enzyme sites, *Not* I at 5' primer and *Eco*R I at 3' primer for the PHD constructs and *Cla* I at 5' primer and *Kpn* I at 3' primer for the C terminal of MLL3 construct.